KIR2DL4 and breast cancer: Here, we established that the abundant expression of HLA-G on breast cancer cells and its engagement with the atypical KIR family receptor, KIR2DL4, on NK cells suppress ADCC and contribute to breast cancer resistance to trastuzumab.